Top

Published in:

01-08-2015 | Research Article

Vitamin D receptor gene polymorphisms and breast cancer risk among postmenopausal Egyptian women

Authors: Eman Abd-Elkader Abd-Elsalam, Nadia A. Ismaeil, Hoda Sibai Abd-Alsalam

Published in: Tumor Biology | Issue 8/2015

Abstract

Many studies reported that vitamin D can protect against various types of cancers. The mechanism of vitamin D action is mediated by the vitamin D receptor (VDR). VDR may have anti-stress function because it has been identified as p53 direct target gene. This research was designed to investigate the role of VDR polymorphisms BsmI (rs 1544410), ApaI (rs 7975232), TaqI (rs 731236), and FokI (rs 10735810) in pathogenesis of breast cancer using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis. The study included 130 postmenopausal breast cancer cases aged 49 to 65 years and 100 controls aged 50 to 72 years. A significantly increased risk of breast cancer among carriers of BsmI bb genotype was observed (OR = 2.5 (1.1–5.6), P = 0.025). Also, a significantly increased risk of breast cancer was detected among women carrying ApaI aa genotype (OR = 2.2 (1.02–4.5), P = 0.04), while no significant associations were observed between breast cancer risk and genotypes and allele frequencies of FokI and TaqI polymorphisms (P > 0.05). Our study showed that VDR gene polymorphisms (BsmI and ApaI) may contribute to breast cancer risk among postmenopausal women.

Bretherton-Watt D, Given-Wilson R, Mansi JL, Thomas V, Carter N, Colston KW. Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. Br J Cancer. 2001;85(2):171–5.CrossRefPubMedPubMedCentral

Buyru N, Tezol A, Yosunkaya-Fenerci E, Dalay N. Vitamin D receptor gene polymorphisms in breast cancer. Exp Mol Med. 2003;35:550–5.CrossRefPubMed

Chen WY, Bertone-Johnson ER, Hunter DJ, Willett WC, Hankinson SE. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:2335–9.CrossRefPubMed

Curran JE, Vaughan T, Lea RA, Weinstein SR, Morrison NA, Griffiths LR. Association of a Vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer. 1999;83:723–6.CrossRefPubMed

Dalessandri KM, Rei M, Wiencke JK, Farren G, Pugh TW, Manjeshwar S, et al. Vitamin D receptor polymorphisms and breast cancer risk in a high-incidence population: a pilot study. J Am Coll Surg. 2012;215(5):652–7.CrossRefPubMed

Engel LS, Orlow I, Sima CS, Satagopan JM, Mujumdar UJ, et al. Vitamin D receptor gene haplotypes and polymorphisms and risk of breast cancer: a nested case-control study. Cancer Epidemiol Biomarkers Prev. 2012;21(10):1856–67.CrossRefPubMedPubMedCentral

Fleet JC, DeSmet M, Johnson R, Li Y. Vitamin D and cancer: a review of molecular mechanisms. Biochem J. 2012;441(1):61–76.CrossRefPubMedPubMedCentral

Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Peckitt C, Bliss J, et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res. 2004;10:5472–81.CrossRefPubMed

Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, et al. Alterations in Vitamin D signaling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer. 2010;10:483.CrossRefPubMedPubMedCentral

10.

Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG, et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer. 2005;41:1164–9.CrossRefPubMed

11.

Marik R, Fackler M, Gabrielson E, Zeiger MA, Sukumar S, et al. DNA methylation-related vitamin D receptor insensitivity in breast cancer. Cancer Biol Ther. 2010;10(1):44–53.CrossRefPubMedPubMedCentral

12.

McCullough ML, Stevens VL, Diver WR, Feigelson HS, Rodriguez C, Bostick RM, et al. Vitamin D pathway gene polymorphisms, calcium intake, and risk of postmenopausal breast cancer. Breast Cancer Res. 2007;9(1):R9.CrossRefPubMedPubMedCentral

13.

McKay JD, McCullough ML, Ziegler RG, Kraft P, Saltzman BS, Riboli E, et al. Vitamin D receptor polymorphisms and breast cancer risk: results from the national cancer institute breast and prostate cancer cohort consortium. Cancer Epidemiol Biomarkers Prev. 2009;18:297–305.CrossRefPubMed

14.

Maruyama R, Aoki F, Toyota M, Sasaki Y, Akashi H, Mita H, et al. Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res. 2006;66:4574–83.CrossRefPubMed

15.

Mathiasen IS, Lademann U, Jäättelä M. Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does Not involve known caspases or p53. Cancer Res. 1999;59(19):4848–56.PubMed

16.

Mehta RG, Moriarty RM, Mehta RR, Penmasta R, Lazzaro G, Constantinou A, et al. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5. J Natl Cancer Inst. 1997;89:212–8.CrossRefPubMed

17.

Mehta RG, Peng X, Alimirah F, Murillo G, Mehta R. Vitamin D and breast cancer: emerging concepts. Cancer Lett. 2012;334(1):95–100.CrossRefPubMed

18.

Mishra DK, Wu Y, Sarkissyan M, Sarkissyan S, Chen Z, Shang X, et al. Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African-American and hispanic women. PLoS One. 2013;8(3):e57967.CrossRefPubMedPubMedCentral

19.

Qi X, Pramanik R, Wang J, Schultz RM, Maitra RK, Han J, et al. The p38 and JNK pathways cooperate to trans-activate vitamin D receptor via c-Jun/AP-1 and sensitize human breast cancer cells to vitamin D(3)-induced growth inhibition. J Biol Chem. 2002;277:25884–92.CrossRefPubMed

20.

Rezende VB, Barbosa Jr F, Montenegro MF, Sandrim VC, Gerlach RF, Tanus-Santos JE. An interethnic comparison of the distribution of vitamin D receptor genotypes and haplotypes. Clin Chim Acta. 2007;384(1–2):155–9.CrossRefPubMed

21.

Rollison DE, Cole AL, Tung KH, Slattery ML, Baumgartner KB, Byers T, et al. Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern U.S. Breast Cancer Res Treat. 2012;132(2):683–91.CrossRefPubMed

22.

Shahbazi S, Alavi S, Majidzadeh-A K, Ghaffarpour M, Soleimani A, Mahdian R. BsmI but not FokI polymorphism of VDR gene is contributed in breast cancer. Med Oncol. 2013;30(1):393–8.

23.

Tang C, Chen N, Wu M, Yuan H, Du Y. FokI polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat. 2009;117:391–9.CrossRefPubMed

24.

Trabert B, Mlone KE, Daling JR, Doody DR, Bernstein L, Ursin G, et al. Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case-control study of Caucasian and African-American women. Breast Cancer Res. 2007;9:R84.CrossRefPubMedPubMedCentral

25.

Vandevyver C, Wylin T, Cassiman JJ, Raus J, Geusens P. Influence of the vitamin D receptor gene alleles on bone mineral density in postmenopausal and osteoporotic women. J Bone Miner Res. 1997;12(2):241–7.CrossRefPubMed

26.

Welsh J. Vitamin D, metabolism in mammary gland and breast cancer. Mol Cell Endocrinol. 2011;347:55–60.CrossRefPubMed

27.

Welsh J. Cellular and molecular effects of vitamin D on carcinogenesis. Arch Biochem Biophys. 2012;523:107–14.CrossRefPubMed

28.

Zhang K, Song L. Association between Vitamin D receptor gene polymorphisms and breast cancer risk: a meta-analysis of 39 studies. PLoS One. 2014;9(4):e96125.CrossRefPubMedPubMedCentral

29.

Zinser GM, Welsh JE. Accelerated mammary gland development during pregnancy and delayed post-lactational involution in vitamin D3 receptor null mice. Mol Endocrinol. 2004;18:2208–23.CrossRefPubMed

30.

Zinser GM, Packman K, Welsh JE. Vitamin D (3) receptor ablation alters mammary gland morphogenesis. Development. 2002;129:3067–76.PubMed

Title: Vitamin D receptor gene polymorphisms and breast cancer risk among postmenopausal Egyptian women
Authors: Eman Abd-Elkader Abd-Elsalam
Nadia A. Ismaeil
Hoda Sibai Abd-Alsalam
Publication date: 01-08-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 8/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3332-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2015

RETRACTED ARTICLE: MiR-335 acts as a potential tumor suppressor miRNA via downregulating ROCK1 expression in hepatocellular carcinoma

Dysregulation of zinc finger protein, X-linked (ZFX) impairs cell proliferation and induces apoptosis in human oral squamous cell carcinorma

The role of tumor suppressor gene SOX11 in prostate cancer

Malic enzyme 1 induces epithelial–mesenchymal transition and indicates poor prognosis in hepatocellular carcinoma

Comparative efficacy of postoperative transarterial chemoembolization with or without antiviral therapy for hepatitis B virus-related hepatocellular carcinoma

Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer